Last reviewed · How we verify

NCT05852184

Hb Scope: A Multi-Center Validation Trial

Completed Last updated 14 July 2025
What this trial tests

trial testing Hb Scope APP in Hemoglobin in 504 participants. Completed in 31 January 2024.

Timeline
1 July 2023
Primary endpoint
31 January 2024
31 January 2024

Quick facts

Lead sponsorChina Medical University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment504
Start date1 July 2023
Primary completion31 January 2024
Estimated completion31 January 2024
Sites3 locations across Taiwan, United Arab Emirates

Drugs / interventions tested

Conditions studied

Sponsor

China Medical University Hospital

Who can join

Adults 20 to 90, any sex, with Hemoglobin or Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The global prevalence of end-stage renal disease (ESRD) was estimated ranging 5.3 to 9.7 million patients in 2017 and is a major healthcare cost driver in both developed and developing economies. The majority of patients with ESRD, approximately 90%, received in-center maintenance hemodialysis (HD). Although HD patients are under the close supervision of a nephrologist, they are vulnerable to anemia and substantial hemoglobin (Hb) variability, which are controversially associated with poor clinical outcomes, such as all-cause mortality. The contemporary narrow target hemoglobin level recommended in the KDIGO and KDOQI guidelines, despite the ongoing debates, poses a crucial challenge in maintaining the optimal hemoglobin level in HD patients. The Big Data Center at China Medical University Hospital (CMUH) has developed a tool, Hb Scope APP, that can use the color of the HD tubing to predict real-time Hb levels by leveraging the smartphone's camera capacity and machine learning (ML) technology. The performance of the Hb Scope ML algorithm in predicting Hb \> 10 g/dL can reach an accuracy of 0.93 and an AUROC of 0.99 in the testing dataset. This opens an opportunity to establish a vibrant digital ecosystem for automatic anemia management. Innovative ML tools must be appropriately regulated before these algorithms are adopted into clinical practice. Therefore, in the current validation study, we propose to do a multicenter validation trial for validating whether the Hb predicted by Hb Scope APP can achieve an area under the receiver operating curve (AUROC) of at least 0.80 in the adult HD populations from CMUH, Asia University Hospital (AUH) in Taiwan, and SEHA Kidney Care (SKC)-Central in the United Arab Emirates.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hemoglobin

Currently open trials in the same condition.

Other China Medical University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05852184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing